Clovis up 10% premarket on positive trial data

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Phase 1 results for Clovis Oncology's (CLVS) EGFR inhibitor CO-1686 show a 64% objective response rate in non-small cell lung cancer patients with the T790M mutation.

Median duration of response is undetermined, but progression-free survival greater than six months has been observed in evaluable heavily-pretreated patients with the T790M mutation.

The drug was well-tolerated in 61 of 62 patients.

The company expects to submit an NDA for CO-1686 in 2015.

202 mutual funds have positions, up from 127 a year earlier.